Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 4/20 | 0.53 |
| ▸ | APLNR | P35414 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641093 | 0.94 | C5AR1 (0.64) | C5AR1MC4ROPRM1OPRD1F2 | |
| SCHEMBL30974009 | 0.91 | C5AR1 (0.62) | C5AR1OPRM1OPRD1F2APLNR | |
| SCHEMBL30948380 | 0.90 | APLNR (0.52) | C5AR1EPHA2OPRM1OPRD1F2 | |
| SCHEMBL31127566 | 0.90 | OPRM1 (0.60) | C5AR1OPRM1OPRD1F2 | |
| SCHEMBL29754594 | 0.89 | C5AR1 (0.70) | C5AR1MC4R | |
| SCHEMBL30523596 | 0.89 | C5AR1 (0.62) | C5AR1MC4RF2APLNR | |
| SCHEMBL30974277 | 0.89 | C5AR1 (0.62) | C5AR1OPRM1F2APLNR | |
| SCHEMBL29880330 | 0.89 | C5AR1 (0.64) | C5AR1MC4REPHA2 | |
| [Val5] - Angiotensin Ii SCHEMBL29551599 | 0.89 | AGTR2 (0.64) | C5AR1EPHA2OPRM1OPRD1F2 | |
| SCHEMBL30903266 | 0.88 | C5AR1 (0.61) | C5AR1MC4REPHA2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711005-A2 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | Stealth BioTherapeutics Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250263433-A1 | METHODS FOR REDUCING CD36 EXPRESSION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12268724-B2 | Methods and compositions for the prevention or treatment of Barth Syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12102659-B2 | Methods for the prevention or treatment of heart failure | CORNELL UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| US-20230149501-A1 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230043587-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4085920-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20220296672-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11420998-B2 | Aromatic-cationic peptides and methods for using same | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11366104-B2 | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-06-21 | — | — | US | disclosed |
| EP-4005582-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043587-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | COL2A1, ALPI, COL14A1 | C5AR1 1277/4885MC4R 261/4885EPHA2 2975/4885 |
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | ARG2, ARGLU1, BCAT1 | C5AR1 4542/4885MC4R 3791/4885EPHA2 4671/4885 |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | TNNI3, TNNT2, FABP3 | C5AR1 1444/4885MC4R 2317/4885EPHA2 3686/4885 |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | C5AR1 1277/4885MC4R 261/4885EPHA2 2975/4885 |
| US-20220296672-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY | NGF, GAP43, PRPH | C5AR1 122/4885MC4R 2175/4885EPHA2 1037/4885 |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | C5AR1 1000/4885MC4R 2331/4885EPHA2 4431/4885 |
| US-12102659-B2 | Methods for the prevention or treatment of heart failure | TNNI3, FABP3, TNNC1 | C5AR1 1061/4885MC4R 1922/4885EPHA2 2643/4885 |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | C5AR1 1000/4885MC4R 2331/4885EPHA2 4431/4885 |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | ARG2, TNNT2, MYLK2 | C5AR1 3385/4885MC4R 2086/4885EPHA2 3179/4885 |
| US-11420998-B2 | Aromatic-cationic peptides and methods for using same | ARG2, ARGLU1, ARG1 | C5AR1 627/4885MC4R 2245/4885EPHA2 4482/4885 |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | C5AR1 1277/4885MC4R 261/4885EPHA2 2975/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | C5AR1 576/4885MC4R 4106/4885EPHA2 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.